Previous meta-analyses of large cardiovascular outcome trials39,40 found that SGLT2 inhibitors have only modest effect on atherosclerotic major adverse cardiovascular outcomes in patients with type 2 diabetes mellitus, and this is confined to those with established atherosclerotic cardiovascular disease (ASCVD). The gene discussed is SLC5A2; the disease is diabetes mellitus.